2019创伤性休克急救复苏创新技术临床应用中国专家共识

2019-01-30 中国研究型医院学会 河南医学研究.2019,28(1):1-7.

为了提高中国创伤性休克及心脏骤停的临床救治技术培训与普及,中国研究型医院学会卫生应急学专业委员会、中国研究型医院学会心肺复苏学专业委员会、河南省医院协会心肺复苏专业委员会共同制定了《2019创伤性休克急救复苏创新技术临床应用中国专家共识》。该共识针对创伤性休克院前无法输血、血浆的紧急情况,解决了容量复苏晶胶液配比与搭配的问题。高渗晶胶复合液救治创伤性休克,用量小,稳定血压效果好,可替代血及血制品,

中文标题:

2019创伤性休克急救复苏创新技术临床应用中国专家共识

发布机构:

中国研究型医院学会

发布日期:

2019-01-30

简要介绍:

为了提高中国创伤性休克及心脏骤停的临床救治技术培训与普及,中国研究型医院学会卫生应急学专业委员会、中国研究型医院学会心肺复苏学专业委员会、河南省医院协会心肺复苏专业委员会共同制定了《2019创伤性休克急救复苏创新技术临床应用中国专家共识》。该共识针对创伤性休克院前无法输血、血浆的紧急情况,解决了容量复苏晶胶液配比与搭配的问题。高渗晶胶复合液救治创伤性休克,用量小,稳定血压效果好,可替代血及血制品,提高了转运至医院的安全性,为抢救生命提供了机会。同时,腹部提压心肺复苏(CPR)解决了创伤后心脏骤停患者不能实施传统胸外按压CPR的救治难题,大大提高了院前创伤性休克患者的救治成功率。鉴于我国急救医疗的实际需求和胸部创伤不能行胸部CPR的特点,采取“政、产、学、研、用”相结合,腹部提压CPR研制成功并推广应用。本专家共识总结了迄今为止国内外已发表的关于创伤性休克与创伤性心脏骤停的科学证据,并基于中国的国情提出了创伤性休克急救复苏创新技术临床应用专家共识。本共识融入了中外创伤性休克及CPR培训的学者智慧与理念,必将使中国创伤性休克与创伤性心脏骤停培训进入一个针对性强、起效快、副作用少、救治率高的新阶段。 

拓展指南:急救相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019创伤性休克急救复苏创新技术临床应用中国专家共识)] GetToolGuiderByIdResponse(projectId=1, id=f20a91c001e05107, title=2019创伤性休克急救复苏创新技术临床应用中国专家共识, enTitle=, guiderFrom=河南医学研究.2019,28(1):1-7., authorId=null, author=, summary=为了提高中国创伤性休克及心脏骤停的临床救治技术培训与普及,中国研究型医院学会卫生应急学专业委员会、中国研究型医院学会心肺复苏学专业委员会、河南省医院协会心肺复苏专业委员会共同制定了《2019创伤性休克急救复苏创新技术临床应用中国专家共识》。该共识针对创伤性休克院前无法输血、血浆的紧急情况,解决了容量复苏晶胶液配比与搭配的问题。高渗晶胶复合液救治创伤性休克,用量小,稳定血压效果好,可替代血及血制品,, cover=, journalId=null, articlesId=null, associationId=1505, associationName=中国研究型医院学会, associationIntro=, copyright=0, guiderPublishedTime=Wed Jan 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>为了提高中国创伤性休克及心脏骤停的临床救治技术培训与普及,中国研究型医院学会卫生应急学专业委员会、中国研究型医院学会心肺复苏学专业委员会、河南省医院协会心肺复苏专业委员会共同制定了《2019创伤性休克急救复苏创新技术临床应用中国专家共识》。该共识针对创伤性休克院前无法输血、血浆的紧急情况,解决了容量复苏晶胶液配比与搭配的问题。高渗晶胶复合液救治创伤性休克,用量小,稳定血压效果好,可替代血及血制品,提高了转运至医院的安全性,为抢救生命提供了机会。同时,腹部提压心肺复苏(CPR)解决了创伤后心脏骤停患者不能实施传统胸外按压CPR的救治难题,大大提高了院前创伤性休克患者的救治成功率。鉴于我国急救医疗的实际需求和胸部创伤不能行胸部CPR的特点,采取“政、产、学、研、用”相结合,腹部提压CPR研制成功并推广应用。本专家共识总结了迄今为止国内外已发表的关于创伤性休克与创伤性心脏骤停的科学证据,并基于中国的国情提出了创伤性休克急救复苏创新技术临床应用专家共识。本共识融入了中外创伤性休克及CPR培训的学者智慧与理念,必将使中国创伤性休克与创伤性心脏骤停培训进入一个针对性强、起效快、副作用少、救治率高的新阶段。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>急救</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=e34af1c0016838c7" title="2018 美国心脏协会关于心肺复苏及心血管急救指南的重点更新:高级心血管生命支持及儿童高级生命支持(中文翻译版)" target=_blank>2018 美国心脏协会关于心肺复苏及心血管急救指南的重点更新:高级心血管生命支持及儿童高级生命支持(中文翻译版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f975d1c0016e8652" title="脑卒中院前急救诊疗指导规范" target=_blank>脑卒中院前急救诊疗指导规范</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=aba3c1c0016e0193" title="2018年美国心脏协会心肺复苏与心血管急救指南更新解读—抗心律失常药物在成人心脏骤停高级生命支持及自主循环恢复后的应用" target=_blank>2018年美国心脏协会心肺复苏与心血管急救指南更新解读—抗心律失常药物在成人心脏骤停高级生命支持及自主循环恢复后的应用</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a101c1c001669589" title="中国急性缺血性脑卒中急诊诊治专家共识院前急救解读" target=_blank>中国急性缺血性脑卒中急诊诊治专家共识院前急救解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=69e961c001661580" title="2018 AHA心肺复苏与心血管急救指南:心跳骤停期间和之后应用抗心律失常药物进行高级生命支持(更新)" target=_blank>2018 AHA心肺复苏与心血管急救指南:心跳骤停期间和之后应用抗心律失常药物进行高级生命支持(更新)</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E6%80%A5%E6%95%91" target=_blank>有关急救更多指南</a></ul>, tagList=[TagDto(tagId=86804, tagName=创伤性休克), TagDto(tagId=24800, tagName=急救复苏)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7696, appHits=765, showAppHits=28, pcHits=5370, showPcHits=2406, likes=272, shares=32, comments=8, approvalStatus=1, publishedTime=Wed Feb 20 21:44:27 CST 2019, publishedTimeString=2019-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Feb 20 21:44:27 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 05:40:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019创伤性休克急救复苏创新技术临床应用中国专家共识)])
2019创伤性休克急救复苏创新技术临床应用中国专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1226204, encodeId=c9c31226204ae, content=非常棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/c8f6859ad6c74a6c856f1aaea1334808/cf4fea39afe44a9baa2be737dc2b8299.jpg, createdBy=0e822518173, createdName=靖哥哥的小狐狸, createdTime=Mon Jun 13 17:17:59 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954046, encodeId=09c895404665, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6252444951, createdName=123e2062m78暂无昵称, createdTime=Mon Apr 05 22:30:36 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902622, encodeId=66e290262277, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbc5410576, createdName=ms3000001135198290, createdTime=Thu Nov 26 22:07:46 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890332, encodeId=5dc889033272, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=7tDTcHWSDibFib0vZXia0FiaCQ&s=100&t=1557457155, createdBy=29c35318878, createdName=木木7242, createdTime=Tue Oct 06 08:27:33 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2022-06-13 靖哥哥的小狐狸

    非常棒!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1226204, encodeId=c9c31226204ae, content=非常棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/c8f6859ad6c74a6c856f1aaea1334808/cf4fea39afe44a9baa2be737dc2b8299.jpg, createdBy=0e822518173, createdName=靖哥哥的小狐狸, createdTime=Mon Jun 13 17:17:59 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954046, encodeId=09c895404665, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6252444951, createdName=123e2062m78暂无昵称, createdTime=Mon Apr 05 22:30:36 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902622, encodeId=66e290262277, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbc5410576, createdName=ms3000001135198290, createdTime=Thu Nov 26 22:07:46 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890332, encodeId=5dc889033272, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=7tDTcHWSDibFib0vZXia0FiaCQ&s=100&t=1557457155, createdBy=29c35318878, createdName=木木7242, createdTime=Tue Oct 06 08:27:33 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2021-04-05 123e2062m78暂无昵称

    好用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1226204, encodeId=c9c31226204ae, content=非常棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/c8f6859ad6c74a6c856f1aaea1334808/cf4fea39afe44a9baa2be737dc2b8299.jpg, createdBy=0e822518173, createdName=靖哥哥的小狐狸, createdTime=Mon Jun 13 17:17:59 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954046, encodeId=09c895404665, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6252444951, createdName=123e2062m78暂无昵称, createdTime=Mon Apr 05 22:30:36 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902622, encodeId=66e290262277, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbc5410576, createdName=ms3000001135198290, createdTime=Thu Nov 26 22:07:46 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890332, encodeId=5dc889033272, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=7tDTcHWSDibFib0vZXia0FiaCQ&s=100&t=1557457155, createdBy=29c35318878, createdName=木木7242, createdTime=Tue Oct 06 08:27:33 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2020-11-26 ms3000001135198290

    好用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1226204, encodeId=c9c31226204ae, content=非常棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/c8f6859ad6c74a6c856f1aaea1334808/cf4fea39afe44a9baa2be737dc2b8299.jpg, createdBy=0e822518173, createdName=靖哥哥的小狐狸, createdTime=Mon Jun 13 17:17:59 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954046, encodeId=09c895404665, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6252444951, createdName=123e2062m78暂无昵称, createdTime=Mon Apr 05 22:30:36 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902622, encodeId=66e290262277, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbc5410576, createdName=ms3000001135198290, createdTime=Thu Nov 26 22:07:46 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890332, encodeId=5dc889033272, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=7tDTcHWSDibFib0vZXia0FiaCQ&s=100&t=1557457155, createdBy=29c35318878, createdName=木木7242, createdTime=Tue Oct 06 08:27:33 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2020-10-06 木木7242

    好用

    0